Does the whole equal the sum of the parts? Patient-assigned utility scores for IBS-related health states and profiles

Health Economics

Volumn 15, Issue 6, 2006, Pages 543-551

  Brazier, John ^a   Dolan, Paul ^a   Karampela, Korina ^b   Towers, Isabel ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Irritable bowel syndrome; Quality adjusted life years; Valuation of health states versus profiles

Indexed keywords

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; HEALTH ECONOMICS; HEALTH STATUS; HEALTH SURVEY; HUMAN; INTERVIEW; IRRITABLE COLON; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

COSTS AND COST ANALYSIS; FEMALE; GREAT BRITAIN; HEALTH STATUS; HUMANS; INTERVIEWS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SICKNESS IMPACT PROFILE;

EID: 33745301145     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1074     Document Type: Article

References (27)

1. Ministry of Health (Ontario). Ontario Guidelines for the Economic Evaluation of Pharmaceutical Products. Ministry of Health: Toronto, 1994.
2. Commonwealth Department of Health, Housing and Community Service. Guidelines for the Pharmaceuticals Industry on the Submission to the Pharmaceutical Benefits Advisory Committee. Australian Government Publishing Service: Canberra, 1992.
3. Department of Health and the Association of the Pharmaceutical Industry. Guidelines for the Economic Evaluation of Pharmaceuticals [Press release]. Department of Health: London, 1994.
4. Bleichrodt H, Wakker P, Johannesson M. Characterizing QALYs by risk neutrality. J Risk Uncertainty 1997; 15: 107-114.
5. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990; 300: 230-235.
6. Richardson J, Hall J, Salkfeld G. The measurement of utility in multiphase health states. Int J Technol Assess Health Care 1996; 12: 151-162.
7. Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 1989; 9: 142-149; 10(2): 148-149.
8. Lipscomb J. The preference for health in cost-effectiveness analysis. Med Care 1989; 27: S233-S253.
9. Mackeigan LD, O'Brien BJ, Oh PI. Holistic versus composite preferences for lifetime treatment sequences for type 2 diabetes. Med Decis Making 1999; 19: 113-121.
10. Varey C, Kahneman D. Experiences extended across time: evaluation of moments and episodes. J Behav Decis Making 1992; 5: 169-185.
11. Chapman GB. Preferences for improving and declining sequences of health outcomes. J Behav Decis Making 2000; 13: 203-218.
12. Ariely D, Carmon Z. Gestalt characteristics of experiences: the defining features of summarized events. J Behav Decis Making 2000; 13: 191-201.
13. Kahneman D, Fredrickson BL, Schreiber CA, Redelmeier DA. When more pain is preferred to less: adding a better end. Psychol Sci 1993; 4: 401-405.
14. Redelmeier DA, Kahneman D. On the discrepancy between experiences and memories: patients' real-time and retrospective evaluations of the pain of colonoscopy. Working Paper, 1993.
15. Dolan P, Gudex C, Kind P, Williams A. Valuing health states: a comparison of methods. J Health Econ 1996; 15: 209-231.
16. Jones-Lee M, Loomes G, O'Reilly D, Phillips P. The value of preventing non-fatal road injuries: findings of a willingness-to-pay national sample survey. Transport Research Laboratory, 1993.
17. O'Brien BJ, Drummond MF. Statistical versus quantitative significance in the socioeconomic evaluation of medicines. Pharmaco Economics 1994; 5: 389-398.
18. Slovic P. The construction of preferences. Am Psychol 1995; 50(5): 364-371.
19. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53-72.
20. Dolan P. Modelling valuations for EuroQol health states. Med Care 1997; 35: 351-363.
21. Kind P. The EuroQol instrument: an index of health-related quality of life. In Quality of Life and Pharmaco Economics in Clinical Trials (2nd edn), Spilker B (ed.). Lippincott-Rivera: Philadelphia, PA, 1996; 191-201.
22. Rutten-Van-Mölken M. Costs and effects of pharmacotherapy in asthma and COPD. PhD Thesis, Universitaire Press Maastricht Datawyse Maastricht, 1994.
23. Llewellyn-Thomas H, Sutherland HJ, Tibshirani R, Ciampi A, Till JE, Boyd NF. Describing health states: methodological issues in obtaining values for health states. Med Care 1984; 22: 543-552.
24. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes (2nd edn). Oxford Medical Publications: Oxford, 1997.
25. Brazier JE, Akehurst R, Brennan A et al. Should patients share a greater role in valuing health states? Health Economics and Decision Science Discussion Paper Series no. 04/3, ScHARR, University of Sheffield, 2004.
26. Gafni A, Torrance GW. Risk attitude and time preference in health. Manage Sci 1984; 30: 440-451.
27. Ariely D, Zauberman G. On the making of an experience: the effects of breaking and combining experiences on their overall evaluation. J Behav Decis Making 2000; 13: 219-232.